GlassScriptPhysician profile
Andrew J Overhiser
NPI 1679789549
$1,494.09
in general payments reported to CMS, 2019-2025
18 companies · $533 in 2025
The $533 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.19 · 2021: $149 · 2022: $82.13 · 2023: $265 · 2024: $421 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.24 | 2023-2025 | |
| Medtronic, INC. | $195.92 | 2021-2024 | Pillcam |
| Pfizer INC. | $173.44 | 2022-2025 | |
| Janssen Biotech, INC. | $131.73 | 2022-2025 | Tremfya, Stelara |
| Genzyme Corporation | $117.43 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.29 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $88.93 | 2024 | Entyvio, Eohilia |
| Olympus America INC. | $70.80 | 2024-2025 | Visiglide, Single Use Biopsy Valve (Sterile) |
| Madrigal Pharmaceuticals | $69.88 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $69.09 | 2023 | |
| Merit Medical Systems INC | $68.91 | 2025 | Esophyx |
| Lilly USA, LLC | $45.51 | 2025 | Omvoh |
| Boston Scientific Corporation | $38.18 | 2025 | Overstitch Nxt Endoscopic Suturing System, Wallflex Duodenal |
| Ferring Pharmaceuticals INC. | $27.25 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $26.62 | 2025 | Iqirvo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $22.69 | 2024 | |
| Intercept Pharmaceuticals, INC. | $22.02 | 2025 | |
| Merck Sharp & Dohme LLC | $13.16 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Overhiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.